HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, is featured in a recent interview with David Leichner that was published in “Authority” magazine. The interview was one of a series of interviews with leaders of tech companies. The series, called “Technology Making an Important Positive Social Impact,” spotlights companies working on making monumental positive changes to society, health, and the environment. In the interview, Vajdic talked about his journey to HeartBeam, including the first half of his career, which was spent as a chip designer with Intel Corporation; Vajdic was involved in the design of the first Flash memory, including two patents that transformed Flash from an idea to a product. During the last decade-plus, Vajdic has focused on developing cardiovascular devices with a vision to enable rapid, accurate heart attack detection outside of a medical setting. During the interview, Vajdic described himself as a risk taker and observed that “there is no progress without some significant risk.” He explained that HeartBeam is developing technology that “offers the ability to determine if chest pain or other cardiac symptoms are due to a heart attack, any time, any place. Timely intervention will save many lives,” said HeartBeam CEO and founder Branislav Vajdic, PhD, during the interview. “Our product in development, HeartBeam AIMIGo(TM), is a portable, credit-card-sized device designed to be placed on the chest to take ECG recordings that are immediately transmitted to a clinician for review. This enables a clinician to determine if that patient needs to go to an ER and/or call 911, or if they can stay home and continue with their day. To make that determination, the clinician needs to have a standard-of-care, 12-lead electrocardiogram (“ECG”), a symptom report and patient history. The HeartBeam platform provides all of that information.”
To view the full interview, visit https://ibn.fm/2Wayq
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
